Evidence map›Paper›PMID 39992057›Full record

ArticleCancer biology & therapy2025

CXCR4 confers stemness and radioresistance in chordoma cells.

Chan-Woong Jung, Jeong-Yub Kim, Myung-Jin Park

Abstract read
In one paragraph

Article in Cancer biology & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Chan-Woong JungDivision of Radiation Cancer Research, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Jeong-Yub KimDivision of Radiation Cancer Research, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Myung-Jin ParkDivision of Radiation Cancer Research, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.ORCID 0000-0002-1996-4083

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CXC Chemokine receptor type 4 (CXCR4) is commonly considered a potential marker for cancer stem cells (CSCs). Dedifferentiated-type chordoma (DTC) cells derived from a patient with recurrent chordoma exhibit high CXCR4 expression and demonstrate increased resistance to chemotherapeutic drugs and ionizing radiation (IR) compared to the conventional-type chordoma cell line, U-CH1. However, the precise role of CXCR4 in the stemness and IR resistance of DTC remains unclear. Therefore, this study aims to elucidate the correlation between the expression of CXCR4 and stemness and radioresistance in chordoma. DTC cells expressing CXCR4 (CXCR4

Indexed as

ChordomaNeoplastic Stem CellsRadiation ToleranceReceptors, CXCR4AnimalsCell Line, TumorHumansMiceSignal TransductionSOXB1 Transcription FactorsXenograft Model Antitumor AssaysCXCR4 protein, humanReceptors, CXCR4SOX2 protein, humanSOXB1 Transcription FactorsCancer stem cellsCXCR4dedifferentiated type chordomaionizing radiationSox2STAT3

Identifiers

PMID39992057
PMCPMC11853615

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.